On the safety of 5-[125I]iodo-2'-deoxyuridine--Preclinical evaluation in swine.

Autor: Baranowska-Kortylewicz J; Department of Radiology (Nuclear Medicine), J. Bruce Henriksen Laboratories, Omaha, Nebraska 68198-1045, USA. jbaranow@mail.unmc.edu, Dalrymple GV, Harrison KA, Holdeman KP, Sharp JG, Cohen SM, Lieberman RP, Schneiderman MH, Clausen SR, Hoffman D, Lai J, Schneiderman GS, Helseth L
Jazyk: angličtina
Zdroj: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 1996; Vol. 35 (7), pp. 925-33.
DOI: 10.3109/02841869609104047
Abstrakt: To increase tumor incorporation and minimize hepatic degradation of radio-IUdR, compartmental administration routes are being considered as an alternative to intravenous (i.v.) injections. Although there are significant data on the biodistribution and some reports on radiotoxicity of i.v.-administered 125IUdR, similar results for other routes of delivery are not available. We have undertaken a series of experiments intended to examine radiation effects of 125IUdR after intravesical (3 swine; eight 3 mCi doses at 4-day intervals), intracarotid (3 swine; two 10 mCi doses at 2-week intervals), and intra-aortic (5 swine, single dose of 10 mCi) administration in a swine model. Liver, renal functions, and complete blood counts were monitored throughout the duration of the experiment. Pharmacokinetics, systemic distribution of radioactivity and metabolites were measured. The normal tissue 125IUdR uptake and histology were determined after necropsy. No adverse systemic effects were identified. Clinical observations, laboratory data, and necropsy results were within normal range.
Databáze: MEDLINE